intestinal diseases - Microviable Therapeutics S.L.

Microviable Therapeutics announces Research Collaboration with the University Medical Center Utrecht and Artizan Biosciences Inc.

adminMicroVi2022-07-21T11:38:05+02:0021 de July de 2022|

Gijón, 21st July 2022, Microviable Therapeutics SL, a biotechnology company in preclinical stage developing novel microbiome-derived biotherapeutic products, announced a research agreement with the University Medical Center of Utrecht (The Netherlands) and Artizan Biosciences [...]

Microviable Therapeutics announces Research Collaboration with Venter Pharma and Inmunomet Intolerancia y Disbiosis

adminMicroVi2022-07-08T13:12:03+02:008 de July de 2022|

Gijón, July 7, 2022, Microviable Therapeutics SL, a biotechnology company in preclinical stage developing novel microbiome-derived biotherapeutic products, today announced that it has entered into a research contract with Venter Pharma SL. and Inmunomet [...]